Reversal of SARS-CoV2-Induced Hypoxia by Nebulized Sodium Ibuprofenate in a Compassionate Use Program
Oscar Salva, Pablo A Doreski, Celia S Giler, Dario C Quinodoz, Lucia G Guzmán, Sonia E Muñoz, Mariana N Carrillo, Daniela J Porta, Germán Ambasch, Esteban Coscia, Jorge L Tambini Diaz, Germán D Bueno, Jorge O Fandi, Miriam A Maldonado, Leandro E Peña Chiappero, Fernando Fournier, Hernán A Pérez, Mauro A Quiroga, Javier A Sala Mercado, Carlos Martínez Picco, Marcelo Alejandro Beltrán, Luis A Argañarás, Nicolás Martínez Ríos, Galia I Kalayan, Dante M Beltramo, Néstor H García
Infectious Diseases and Therapy, doi:10.1007/s40121-021-00527-2
Introduction: Sodium ibuprofenate in hypertonic saline (NaIHS) administered directly to the lungs by nebulization and inhalation has antibacterial and anti-inflammatory effects, with the potential to deliver these benefits to hypoxic patients. We describe a compassionate use program that offered this therapy to hospitalized COVID-19 patients. Methods: NaIHS (50 mg ibuprofen, tid) was provided in addition to standard of care (SOC) to hospitalized COVID-19 patients until oxygen saturation levels of[94% were achieved on ambient air. Patients wore a containment hood to diminish aerosolization. Outcome data from participating patients treated at multiple hospitals in Argentina between April 4 and October 31, 2020, are summarized.
References
Ackermann, Verleden, Kuehnel, Haverich, Welte et al., Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19, N Engl J Med
Baraniuk, Lundgren, Mizoguchi, Peden, Gawin et al., Bradykinin and respiratory mucous membranes: analysis of bradykinin binding site distribution and secretory responses in vitro and in vivo, Am Rev Respir Dis
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19-final report, N Engl J Med
Brito-Azevedo, Pinto, Preta, Bouskela, SARS-CoV-2 infection causes pulmonary shunt by vasodilatation, J Med Virol
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in adults hospitalized with severe COVID-19, N Engl J Med
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate COVID-19, N Engl J Med
Das, Can bioactive lipids inactivate coronavirus (COVID-19)?, Arch Med Res
Dill, Patel, Yang, Bachoo, Powell et al., A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons, J Neurosci
Freeman, Peek, Becker, Smith, Denison, Coronaviruses induce entry-independent, continuous macropinocytosis, mBio,
doi:10.1128/mBio.01340-14Garcı ´a, Porta, Alasino, Mun ˜oz, Se et al., Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution, Med Hypotheses
Garvin, Alvarez, Miller, Prates, Walker et al., A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm, Elife
Gholamreza-Fahimi, Bisha, Hahn, Straßen, Krybus et al., Cyclooxygenase activity in bradykinin-induced dermal extravasation. A study in mice and humans, Biomed Pharmacother
Hammock, Gilligan, Panigrahy, Eicosanoids, Am J Pathol
Konstan, Byard, Hoppel, Davis, Effect of high-dose ibuprofen in patients with cystic fibrosis, N Engl J Med
Magro, Mulvey, Berlin, Nuovo, Salvatore et al., Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases, Transl Res
Mccullagh, Nelder, Generalized linear models (monographs on statistics and applied probability)
Mcfadyen, Stevens, Peter, The emerging threat of (Micro)thrombosis in COVID-19 and its therapeutic implications, Circ Res
Mcintyre, Philp, Inwood, Effect of ibuprofen on platelet function in normal subjects and hemophiliac patients, Clin Pharmacol Ther
Mun ˜oz, Alasino, Garro, Heredia, Garcı ´a et al., High concentrations of sodium chloride improve microbicidal activity of ibuprofen against common cystic fibrosis pathogens, Pharmaceuticals
Serhan, Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators, J Thromb Haemost
Shi, Han, Jiang, Cao, Alwalid et al., Radiological findings from 81 patients with COVID-study, Lancet Infect Dis
Simonovich, Pratx, Scibona, Beruto, Vallone et al., A randomized trial of convalescent plasma in COVID-19 severe pneumonia, N Engl J Med
Smith, Redfern, Pimentel, Collins, Malycha, The National Early Warning Score 2 (NEWS2), Clin Med
Stone, Frigault, Serling-Boyd, Fernandes, Harvey et al., Efficacy of tocilizumab in patients hospitalized with COVID-19, N Engl J Med
Swaine, Dittmar, CDC42 use in viral cell entry processes by RNA viruses, Viruses
Tsubouchi, Mukai, Kawahito, Yamada, Kohno et al., Meloxicam inhibits the growth of non-small cell lung cancer, Anticancer Res
Walsh, Low-dose aspirin: treatment for the imbalance of increased thromboxane and decreased prostacyclin in preeclampsia, Am J Perinatol
Zamudio-Meza, Castillo-Alvarez, Gonza ´lez-Bonilla, Meza, Cross-talk between Rac1 and Cdc42 GTPases regulates formation of filopodia required for dengue virus type-2 entry into HMEC-1 cells, J Gen Virol
Zhou, Nonsteroidal anti-inflammatory drugs can lower amyloidogenic A 42 by inhibiting rho, Science
